Company Directory - Arvinas Inc
Company Details - Arvinas Inc
Arvinas Inc
WebsiteNew Haven, USA
Arvinas Inc is a clinical-stage biopharmaceutical company pioneering targeted protein degradation (PROTAC) therapies. The company focuses on developing novel treatments for cancer and other serious diseases by harnessing the body’s natural protein degradation processes.
CCI Score
CCI Score: Arvinas Inc
-38.83
0.02%
Latest Event
Shareholder Alert Investigation on Alleged Securities Fraud
Pomerantz LLP is investigating claims that Arvinas, Inc. and certain of its officers or directors may have engaged in securities fraud or other unlawful business practices. The investigation was prompted following a sharp stock price decline after the postponed Phase 3 trial for its breast cancer therapy, raising concerns over the company’s ethical standards and potential erosion of shareholder trust.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
TOADIE
Arvinas Inc is currently rated as a Toadie.
Latest Events
- JAN282025
Pomerantz LLP is investigating claims that Arvinas, Inc. and certain of its officers or directors may have engaged in securities fraud or other unlawful business practices. The investigation was prompted following a sharp stock price decline after the postponed Phase 3 trial for its breast cancer therapy, raising concerns over the company’s ethical standards and potential erosion of shareholder trust.
-40
Business Practices and Ethical Responsibility
March 26
This investigation highlights serious concerns regarding potentially unethical business practices at Arvinas, Inc. Allegations of securities fraud and other misconduct suggest lapses in corporate governance that undermine transparency and accountability. Such behavior can erode democratic norms by diminishing trust in corporate oversight, indirectly facilitating authoritarian influences. The fact that these issues emerged amid a sharp drop in the company’s stock underscores the potential financial and reputational damage resulting from such practices.
- DEC032024
An investigation by Pomerantz LLP is looking into alleged fraudulent activities, including misleading investors and delaying a Phase 3 breast cancer trial, raising concerns about Arvinas' business ethics and corporate governance.
-40
Business Practices and Ethical Responsibility
March 26
The investigation into Arvinas, Inc. raises serious concerns regarding its business practices and ethical responsibilities. Allegations of fraudulent securities practices and the delay in the Phase 3 trial for a breast cancer treatment suggest that the company may have misled investors about its operational and financial status, undermining trust. Such corporate misconduct is indicative of broader systemic issues in corporate governance that can contribute to the erosion of accountability, which aligns with complicity in authoritarian practices by prioritizing profit over transparency and ethical responsibility.
Investigation Launched Into Arvinas, Inc. Investor Claims - Investors Hangout
Alternatives
Kenilworth, United States
2.89
Corporation
2.31
Corporation
1.66
Corporation
1.00
Copenhagen, Denmark
2.36
Corporation
3.48
Corporation
0.00
Corporation
-43.74
Raleigh, USA
56.52
USA
0.00
Industries
- 325412
- Pharmaceutical Preparation Manufacturing
- 541712
- Research and Development in the Physical, Engineering, and Life Sciences (Biotechnology)
- 541711
- Research and Development in Biotechnology